Angiogenesi nel NSCLC: stato dell arte
|
|
- Elmer Mitchell
- 6 years ago
- Views:
Transcription
1 Angiogenesi nel NSCLC: stato dell arte Andrea Camerini Oncologia Medica - Ospedale Versilia Investigator Meeting Study GOIRC
2 Overview Neoangiogenesis in NSCLC (among others) Lots of targets lots of drugs Bevacizumab in first-line treatment Some criticisms (pts selection, predictive factors, toxicities)
3 Neoangiogenesis in NSCLC (among others)
4 Angiogenesi: a hallmark of cancer Activating invasion & metastasis Genome instability mutation Tumourpromoting inflammation Resisting cell death Enabling replicative immortality Degrading cellular energetics Sustaining proliferative signalling Avoiding immune destruction Evading growth suppressors Inducing angiogenesis Anti-VEGF therapy Regression of existing tumour vasculature Inhibition of new vessel growth No bone marrow suppression No cumulative toxicities Improved efficacy in combination with a well-established safety profile Hanahan & Weinberg. Cell 2011
5 Angiogenesis is a key element in the development of different types of tumors 1 A tumor mass larger than mm 2 has outgrown its capacity to acquire nutrients by simple diffusion and must initiate angiogenesis through host vessel initiation of capillary sprouts in the direction of the tumor 1 1. Folkman. In: Kufe, Pollock, Weichselbaum, eds. Cancer Medicine (Holland). 6th ed. Hamilton, Ontario: BC Decker; 2000; 2. Bergers, Benjamin. Nat Rev Cancer. 2003;3:401-10; 3. *Folkman. N Engl J Med. 1971;285:1182-6; 4. J Natl Cancer Inst. 1990;82:4-6 *«This article is copyrighted by the Massachusetts Medical Society. All rights reserved. It is provided for your personal informational use only»
6 Jain NEJM 2009
7 TYPE OF MOLECULES MOLECULES RECEPTOR FUNCTION ANGIOGENIC MOLECULES VEGF Family VEGF-A VEGFR-1 VEGFR-2 FGF Family FGF-2 FGFR-1 FGFR-2 FGFR-3 FGFR-4 Angiopoietin (Ang) Metalloproteinases (MMP) Cytokines Ang-1* Ang-2 MMP-2 MMP-9 TNF-α TGF-β CXC Chemokines CXC-ELR + CXCR2 CXCR4 CXCR7 Tie-1 Tie-2 None Substrate: Basement Membrane (BM) Extracellular Matrix (ECM) TNFR TβRI TβRII Proliferation (EC, P) Migration (EC) Formation of tubular structures Proliferación (EC, F) Migration (EC) VEGF Expression Formation of capillary structure Inflammation- related genes Sprouting*, proliferation, migration, vessel stabilization* (EC) Recruitment and activation of mural cells Degradation of BM and ECM Migration (EC) Migration (EC) Tube formation Vessel stabilization Inflammation Tube formation Proliferation, migration, inflammation (EC) Secretion and activation of MMPs Transcription factors HIF-1α* NF-κB** AP-1*** *Expression of VEGF, VEGFR, CXCL8 bfgf **Expression of CXCR2, CCL5, CXCL8 ***CXCL8 ANGIOSTATIC MOLECULES Angiostatin --- None. Proliferación (EC) Angiosotatin binds several proteins: Angiomotin ATP synthase Integrins Annexin II NG2 proteoglycan Endostatin --- None Endostatin binds several proteins Migration (EC) Formation of capillary structure VEGF Expression Proliferación (EC) Apoptosis Migration (EC) Inhibition MMPs Acivation VEGF Expression CXC Chemokines CXC-ELR - CXCR3B Migratory form Proliferation Formation of capillary structures Cytokines INF-γ INFgammaRI INFgammaRII *Expression of angiostatic chemokines Angiogenesis MMPs Inhibitors: TIMP TIMP-2 TIMP-3 Inhibition of MMPs Migratory form Proliferation Formation of capillary structures Abbreviations: AP-1, Activator Protein 1;BM, Basement Membrane; EC, Endothelial Cells; EpC Ephitelial Cells, ECM, Extracellular Matrix; FGF, Fibroblast Growth Factor; F, Rivas-Fuentes J Cancer 2015
8 Epigenetic induction Hypoxia, cytokines, sex hormones, growth factors, chemokines Genetic induction Mutant p53, VHL, PTEN-suppressor genes, and activated oncogenes (e.g., ras, src, EGFR, and erbb-2/her2) VEGF B PlGF VEGF A 121 VEGF A 165 VEGF C VEGF D S S S S Plasma membrane VEGFR-1 (flt-1) NRP-1 NRP-2 PLCγ VEGFR-2 (flk-1/kdr) VEGFR-3 (flt-4) Endothelial cell Raf PKC Host VEGF PI3K Akt MEK Vascular permeability MAPK Proliferation Survival Migration Mobilization (e.g., of VEGFR-2+ endothelial progenitor cells) Kerbel NEJM 2008
9 urthermore, chemokines and their receptors hemokine ligand/receptor axis involved in the pathophysiology of NSCLC. The pathophysiology of NSCLC involve Rivas-Fuentes J Cancer 2015
10 VEGF is an early and persistent promoter of tumour angiogenesis 1 4 VEGF VEGF bfgf TGFβ-1 VEGF bfgf TGFβ-1 PLGF VEGF bfgf TGFβ-1 PLGF PD-ECGF VEGF bfgf TGFβ-1 PLGF PD-ECGF Pleiotrophin Continued VEGF expression 3 Tumours continually require VEGF to recruit new vasculature 5 Graphical elaboration from text data VEGF continues to be expressed throughout tumor progression, even as secondary pathways emerge 2,3,6,7 1. Bergers, Benjamin. Nat Rev Cancer. 2003;3:401-10; 3; 2. Kim, et al. Nature ;362:841-4; 3. Folkman. In: DeVita, Hellman, Rosenberg, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins;2005; 4. Ferrara, et al. Nat Med. 2003;9:669-76; 5. Inoue, et al. Cancer Cell ;2: ; 6. Mesiano, et al. Am J Pathol ;153: ; 7. Melnyk, et al. J Urol. 1999;161:960-3
11
12 1. Avastin Summary of Product Characteristics; 2. Presta, et al. Cancer Res. 1997;57: Bevacizumab precisely targets VEGF to inhibit angiogenesis, for continuous tumour control 1,2 VEGF VEGF receptor Bevacizumab Bevacizumab prevents binding of VEGF to receptors 1,2 Bevacizumab has a long elimination half life (approximately 20 days) 1
13 Bevacizumab exerts multiple effects that contribute to increased treatment efficacy compared to conventional treatments 1 20 Graphical elaboration from text data Regression of existing tumour vasculature 1 3 Inhibition of new vessel growth 1 3,8 Anti-permeability of surviving vasculature Consistently increased response rates 4 7 Continuous control of tumour growth 8 10 Reduction of ascites and effusions 2,3,11, Baluk, et al. Curr Opin Genet Dev. 2005; 15:102-11; 2. Willett, et al. Nat Med. 2004;10:145-7; 3. O Connor, et al. Clin Cancer Res. 2009;15: ; 4. N Engl J Med. 2004; 350: ; 5. Sandler, et al. N Engl J Med ;355: ; 6. Escudier, et al. Lancet ;370: ; 7. Miller, et al. N Engl J Med ;357: ; 8. Mabuchi, et al. Clin Cancer Res ; 14:7781-9; 9. Wild, et al. Int J Cancer ;110(3):343-51; 10. Gerber, Ferrara. Cancer Res ;65:671-80; 11. Prager, et al. Mol Oncol. 2010;4:150-60; 12. Yanagisawa, et al. Anticancer Drugs. 2010;21:687-94; 13. Dickson, et al. Clin Cancer Res ;13: ; 14. Hu, et al. Am J Pathol ;161: ; 15. Ribeiro, et al. Respirology ;14: ; 16. Watanabe, et al. Hum Gene Ther ;20: ; 17. Mesiano, et al. Am J Pathol. 1998;153: ; 18. Bellati, et al. Invest New Drugs ;28:887-94; 19. Huynh, et al. J Hepatol ;49:52-60; 20. Ninomiya, et al J. Surg Res ;154:
14 Lots of targets lots of drugs
15 TABLE 1 Recent phase III trials assessing antiangiogenic agents in a first-line setting Agent and study name [ref.] Target (s) Study design Overall response rate Progression-free survival Overall survival Monoclonal antibodies Bevacizumab; ECOG 4599 [14] Bevacizumab; AVAiL [21, 22] Multi-targeted antiangiogenic orally administered TKIs Cediranib; BR24 [23] Cediranib; BR29 [24] Sorafenib; ESCAPE [25] Sorafenib; NExUS [26] Motesanib; MONET1 [27] Vascular disrupting agents Vadimezan; ATTRACT-1 [28] VEGF VEGF VEGFR-1 3, PDGFR-b, FGFR-1 and c-kit VEGFR-1 3, PDGFR-b, FGFR-1 and c-kit VEGFR-2 3, PDGFR-b, c-kit, Raf and flt-3 VEGFR-2 3, PDGFR-b, c-kit, Raf and flt-3 VEGFR-1 3, PDGFR-b, c-kit and RET Stage IIIB/IV non-squamous NSCLC Patients randomised to: carboplatin/paclitaxel (n5444) or carboplatin/paclitaxel + bevacizumab (15 mg?kg -1 ;n5434) Primary end-point: overall survival Stage IIIB/IV non-squamous NSCLC Patients randomised to: cisplatin/ gemcitabine (n5347), cisplatin/ gemcitabine + bevacizumab (7.5 mg?kg -1 ;n5345) or cisplatin/ gemcitabine + bevacizumab (15 mg?kg -1 ;n5351) Primary end-point: progression-free survival Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n5125) or carboplatin/paclitaxel + cediranib (30 mg?day -1 ;n5126) Primary end-point: progressionfree survival Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel or carboplatin/ paclitaxel + cediranib (20 mg?day -1 ) Primary end-point: overall survival Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n5462) or carboplatin/paclitaxel + sorafenib (400 mg; n5464) Primary end-point: overall survival Stage IIIB/IV non-squamous NSCLC Patients randomised to: gemcitabine/cisplatin (n5387) or gemcitabine/cisplatin + sorafenib (400 mg; n5385) Primary end-point: overall survival Stage IIIB/IV non-squamous NSCLC Patients randomised to: carboplatin/paclitaxel (n5549) or carboplatin/paclitaxel + motesanib (125 mg; n5541) Primary end-point: overall survival Stage IIIB/IV NSCLC all histologies Patients randomised to: carboplatin/paclitaxel (n5650) or carboplatin/paclitaxel + vadimezan (1800 mg?m -2 ;n5649) Primary end-point: overall survival Carboplatin/paclitaxel: 15% Carboplatin/paclitaxel + bevacizumab: 35% (p,0.001) Cisplatin/gemcitabine: 20.1% Cisplatin/gemcitabine + bevacizumab (7.5 mg?kg -1 ): 34.1% Cisplatin/gemcitabine + bevacizumab (15 mg?kg -1 ): 30.4% (p, and p , respectively) Carboplatin/paclitaxel: 16% Carboplatin/paclitaxel + cediranib: 38% (p,0.0001) Carboplatin/paclitaxel: 34% Carboplatin/paclitaxel + cediranib: 52% (p50.001) Carboplatin/paclitaxel: 27% Carboplatin/paclitaxel + sorafenib: 24% (p50.102) Gemcitabine/cisplatin: 26% Gemcitabine/cisplatin + sorafenib: 28% (p50.27) Carboplatin/paclitaxel: 26% Carboplatin/paclitaxel + motesanib: 40% (p,0.001) Carboplatin/paclitaxel: 25% Carboplatin/paclitaxel + vadimezan: 25% (p51.0) Carboplatin/paclitaxel: 4.5 months Carboplatin/paclitaxel + bevacizumab: 6.2 months HR 0.66 (95% CI ); p,0.001 Cisplatin/gemcitabine: 6.1 months Cisplatin/gemcitabine + bevacizumab (7.5 mg?kg -1 ): 6.7 months Cisplatin/gemcitabine + bevacizumab (15 mg?kg -1 ): 6.5 months HR 0.75 (95% CI ); p and HR 0.92 (95% CI ); p50.03, respectively Carboplatin/paclitaxel: 5.0 months Carboplatin/paclitaxel + cediranib: 5.6 months HR 0.77 (95% CI ); p50.13 Carboplatin/paclitaxel: 5.5 months Carboplatin/paclitaxel + cediranib: 5.5 months HR 0.91 (95% CI ); p50.5 Carboplatin/paclitaxel: 5.4 months Carboplatin/paclitaxel + sorafenib: 4.6 months HR 0.99 (95% CI ); p Gemcitabine/cisplatin: 5.5 months Gemcitabine/cisplatin + sorafenib: 6.0 months HR 0.83 (95% CI ); p Carboplatin/paclitaxel: 5.4 months Carboplatin/paclitaxel + motesanib: 5.6 months HR 0.79 (95% CI ); p,0.001 Carboplatin/paclitaxel: 5.5 months Carboplatin/paclitaxel + vadimezan: 5.5 months HR 1.04 (95% CI ); p Carboplatin/paclitaxel: 10.3 months Carboplatin/paclitaxel + bevacizumab: 12.3 months HR 0.79 (95% CI ); p Cisplatin/gemcitabine: 13.1 months Cisplatin/gemcitabine + bevacizumab (7.5 mg?kg -1 ): 13.6 months Cisplatin/gemcitabine + bevacizumab (15 mg?kg -1 ): 13.4 months HR 0.92 (95% CI ); p and HR 1.03 (95% CI ); p50.761, respectively Carboplatin/paclitaxel: 10.1 months Carboplatin/paclitaxel + cediranib: 10.5 months HR 0.78 (95% CI ); p50.11 Carboplatin/paclitaxel: 12.1 months Carboplatin/paclitaxel + cediranib: 12.2 months HR 0.95 (95% CI ); p50.74 Carboplatin/paclitaxel: 10.6 months Carboplatin/paclitaxel + sorafenib: 10.7 months HR 1.15 (95% CI ); p Gemcitabine/cisplatin: 12.5 months Gemcitabine/cisplatin + sorafenib: 12.4 months HR 0.98 (65% CI ); p Carboplatin/paclitaxel: 11.0 months Carboplatin/paclitaxel + motesanib: 13.0 months HR 0.90 (95% CI ); p50.14 Carboplatin/paclitaxel: 12.7 months Carboplatin/paclitaxel + vadimezan: 13.4 months HR 1.01 (95% CI ); p Crinò L, Eur Respir Rev 2014
16 TABLE 2 Recent phase III trials assessing antiangiogenic agents in a second- or third-line setting Agent and study name [ref.] Target (s) Study design Overall response rate Progression-free survival Overall survival Multi-targeted antiangiogenic orally administered TKIs Nintedanib; LUME-Lung 1[44] Nintedanib; LUME-Lung 2 [45] Vandetanib; ZODIAC [46] Vandetanib; ZEAL [47] Vandetanib; ZEPHYR [48] Vandetanib; ZEST [49] Sorafenib; MISSION [50] Sunitinib [51] VEGF-1 3, PDGF-a and b, andfgfr-1 3 VEGF-1 3, PDGF-a and b, andfgfr-1 3 VEGFR-1 and -2, RET and EGFR VEGFR-1 and -2, RET and EGFR VEGFR-1 and -2, RET and EGFR VEGFR-1 and -2, RET and EGFR VEGFR-2 3, PDGFR-b, c-kit, Raf and flt-3 VEGF-1 3, PDGFR-a and b, andret Stage IIIB/IV NSCLC all histologies Patients randomised to: docetaxel (n5659) or docetaxel + nintedanib (200 mg twice daily; n5655) Primary end-point: progressionfree survival Stage IIIB/IV non-squamous NSCLC Patients randomised to: pemetrexed (n5360) or pemetrexed + nintedanib (200 mg twice daily; n5353) Primary end-point: progressionfree survival Stage IIIB/IV NSCLC all histologies Patients randomised to: docetaxel (n5697) or docetaxel + vandetanib (100 mg?day -1 ;n5694) Primary end-point: progressionfree survival Stage IIIB/IV NSCLC all histologies Patients randomised to: pemetrexed (n5278) or pemetrexed + vandetanib (100 mg?day -1 ;n5256) Primary end-point: progressionfree survival Stage IIIB/IV NSCLC all histologies Pre-treated with EGFR inhibitor and one or two chemotherapy regimens Patients randomised to: placebo (n5307) or vandetanib (300 mg?day -1 ;n5617) Primary end-point: overall survival Stage IIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg?day -1 ;n5617) or vandetanib (300 mg?day -1 ;n5623) Primary end-point: progressionfree survival Stage IIIB/IV non-squamous NSCLC Patients randomised to: placebo (n5353) or sorafenib (400 mg twice daily; n5350) Primary end-point: overall survival Stage IIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg?day -1 ;n5480) or erlotinib + sunitinib (37.5 mg?day -1 ;n5480) Primary end-point: overall survival Monoclonal antibodies, decoy receptors Bevacizumab; BeTa [52] VEGF StageIIIB/IV NSCLC all histologies Patients randomised to: erlotinib (150 mg?day -1 ;n5317) or erlotinib + bevacizumab (n5319) Primary end-point: progressionfree survival Aflibercept; VITAL [53] VEGF Non-squamousNSCLC Patients randomised to: docetaxel (n5457) or docetaxel + aflibercept (6 mg?day -1 ;n5456) Primary end-point: overall survival Overall response rate not reported DCR was significantly greater in the docetaxel + nintedanib arm in patients with adenocarcinoma (p,0.0001) No difference in overall response rate between pemetrexed and pemetrexed + nintedanib (9%) Pemetrexed: DCR 53% Pemetrexed + nintedanib: DCR 61% (p50.039) Docetaxel: 10% Docetaxel + vandetanib: 17% (p ) Pemetrexed: 8% Pemetrexed + vandetanib: 19% (p,0.001) Placebo: 0.7% Vandetanib: 2.6% (p50.028) Erlotinib: 12% Vandetanib: 12% (p50.98) Placebo: 0.9% Sorafenib: 4.9% (p,0.001) Erlotinib: 6.9% Erlotinib + sunitinib: 10.6% (p50.048) Erlotinib: 6% Erlotinib + bevacizumab: 13% (p-value NR) Docetaxel: 8.9% Docetaxel + aflibercept: 23.3% (p,0.001) Docetaxel: 2.7 months Docetaxel + nintedanib: 3.4 months HR 0.79 (CI ); p Pemetrexed: 3.6 months Pemetrexed + nintedanib: 4.4 months HR 0.83 (95% CI ); p50.04 Docetaxel: 3.2 months Docetaxel + vandetanib: 4.0 months HR 0.79 (97.6% CI ); p, Pemetrexed: 11.9 weeks Pemetrexed + vandetanib: 17.6 weeks HR 0.86 (97.6% CI ); p Placebo: 1.8 months Vandetanib: 1.9 months HR 0.63 (95.2% CI ); p,0.001 Erlotinib: 2.0 months Vandetanib: 2.6 months HR 0.98 (95.2% CI ); p Placebo: 43 days Sorafenib: 84 days HR 0.61; p, Erlotinib: 2.0 months Erlotinib + sunitinib: 3.6 months HR 0.81 (95% CI ); p Erlotinib: 1.7 months Erlotinib + bevacizumab: 3.4 months HR 0.62 (95% CI ); p-value NR Docetaxel: 4.1 months Docetaxel + aflibercept: 5.2 months HR 0.82 (95% CI ); p In patients with adenocarcinoma: Docetaxel: 10.3 months Docetaxel + nintedanib: 12.6 months HR 0.83; p In overall population: Docetaxel: 9.1 months Docetaxel + nintedanib: 10.1 months HR 0.94; p No significant difference (median values NR) Docetaxel: 10.0 months Docetaxel + vandetanib: 10.6 months HR 0.91 (97.5% CI ); p Pemetrexed: 9.2 months Pemetrexed + vandetanib: 10.5 months HR 0.86 (97.5% CI ); p Placebo: 7.8 months Vandetanib: 8.5 months HR 0.95 (95.2% CI ); p Erlotinib: 7.8 months Vandetanib: 6.9 months HR 1.01 (95.1% CI ); p Placebo: 253 days Sorafenib: 248 days HR 0.99; p Erlotinib: 8.5 months Erlotinib + sunitinib: 9.0 months HR 0.92 (95% CI ); p Erlotinib: 9.2 months Erlotinib + bevacizumab: 9.3 months HR 0.97 (95% CI ); p Docetaxel: 10.4 months Docetaxel + aflibercept: 10.1 months HR 1.01 (95% CI ); p50.9 Crinò L, Eur Respir Rev 2014
17 Bevacizumab in first-line treatment
18 Bevacizumab-based therapy extends survival beyond historical benchmark of 1 year* 2006 Carboplatin + paclitaxel + bevacizumab: 12.3 months 5 E4599 Non- squamous histology 2006 Carboplatin + paclitaxel: 10.3 months 5 E s Cisplatin + pemetrexed: 11 months s Platinum doublets: 8 months 3 All comers 1980s Single-agent platinum: 6 8 months s BSC: 2 5 months 1 0 3,5 7 10,5 14 Graphical elaboration from text data Median survival (months) *data are not directly comparable because of differences in criteria between trials 1. Ganz, et al. Cancer 1989, 63: ; 2. Bunn, et al. Clin Cancer Res 1998;4: ; 3. **Schiller, et al. N Engl J Med 2002;346:92-8; 4. Scagliotti, et al. The Oncologist 2009, 14: ; 5. **Sandler A et al. N Engl J Med. 2006;355:
19 E4599: trial design Previously untreated stage IIIB, IV or recurrent predominantly non-squamous NSCLC (n=878) CP q3w x 6 (n=444) Bevacizumab (15mg/kg) + CP q3w x 6 (n=434) Bevacizumab PD* PD Graphical elaboration from text data Primary endpoint - overall survival (OS) *No crossover permitted CP = carboplatin/paclitaxel PD = progressive disease Secondary endpoints - objective response rate - progression-free survival (PFS) - duration of response - safety Sandler A et al. N Engl J Med. 2006;355:
20 Bevacizumab-based therapy extends survival beyond historical benchmark of 1 year E4599 overall patient population HR (95% CI) CP (n=444) Bevacizumab 15mg/kg + CP (n=434) 0.79 ( ) p value Median OS (months) Graphical elaboration from text data Sandler A et al. N Engl J Med. 2006;355:
21 E4599: OS benefit in pre-planned analysis of adenocarcinoma histology 1.0 CP (n=302) Bev 15mg/kg + CP (n=300) Estimated probability HR (95% CI) 0.69 ( ) Median OS (months) months (95% Cl) 24 months (95% Cl) 0,565 (0,508 0,621) 0,271 (0,216 0,326) 0,433 (0,376 0,490) 0,168 (0,121 0,216) Adapted from Sandler A et al. J Thorac Oncol. 2010;5:
22 AVAiL: trial design 2 Bevacizumab (15mg/kg) + CG q3w x 6 (n=351) Bevacizumab PD Previously untreated, stage IIIB, IV or recurrent non-squamous NSCLC (n=1,043) RA ND OM I SE 1 1 Placebo (15mg/kg) + CG q3w x 6 (n=347) Placebo (7.5mg/kg) + CG q3w x 6 Placebo PD 2 Bevacizumab (7.5mg/kg) + CG q3w x 6 (n=345) Bevacizumab PD CG = cisplatin/gemcitabine; PD = progressive disease Graphical elaboration from text data Primary endpoint progression-free survival (PFS) Secondary endpoints overall survival (OS) objective response rate safety Reck, et al J Clin Oncol. 2009;27:
23 AVAiL: primary endpoint PFS bevacizumab7,5 mg/kg bevacizumab 15 mg/kg Median PFS = 6,8 months HR=0,75 (CI 95% 0,64-0,87) p=0,0003 Median PFS = 6,6 months HR=0,85 (CI 95% 0,73-1,00) p=0,0456 bevacizumab 15 mg/kg + GC Plot of Kaplan-Meier estimates for progression-free survival (intent-totreat population) for the (A) 7.5 mg/kg bevacizumab (Bev) arm and (B) 15 mg/kg bevacizumab arm compared with placebo. CG, cisplatin plus gemcitabine; HR, hazard ratio. Reck, et al J Clin Oncol. 2009;27:
24 AVAiL: trend towards improved OS in bevacizumab-treated patients not receiving post-protocol therapies* Median OS (95% CI) No 2nd-line Bev groups 8.7 ( ) Placebo 7.3 ( ) HR (p value) Bev to placebo 0.84 (0.20) Graphical elaboration from text data *Exploratory analysis Reck, et al, Ann Oncol ;21: Plots of Kaplan Meier estimates for OS (ITT population) for the bevacizumab 7.5 mg/kg group and the bevacizumab 15 mg/kg group relative to placebo, together with time to event data for the subgroup of patients who did not receive post study therapy
25 A Overall Survival (proportion) Randomly assigned treatment PI + CP B + CP Median OS 17.7 v 24.3 months HR, 0.68; 95% CI, 0.50 to 0.93 P = Time of Study (month) No. at risk PI + CP B + CP Zhou C, JCO 2015
26 100 HR 0 54 (95% CI ) Progression-free survival (%) Number at risk Erlotinib plus bevacizumab group Erlotinib alone group Erlotinib plus bevacizumab group (median 16 0 months [95% CI ]; 46 events) Erlotinib alone group (median 9 7 months [95% CI ]; 57 events) Time (months) Figure 2: Progression-free survival, as determined by independent review committee, in the modified A Erlotinib plus bevacizumab group Responder (CR or PR) Non-responder (SD, PD, or NE) 20 Change in SLD (%) B Erlotinib alone group Change in SLD (%) Seto T, Lancet Oncol Figure 4: Waterfall plot of best percentage change from baseline in the sum of longest tumour diameters
27 Improved outcomes with bevacizumab: meta-analysis of data from RCTs OS PFS Costa Lima BC, PLOS ONE, August 2011; Vol 6,Issue 8, e22681
28 Improved outcomes with bevacizumab: meta-analysis of data from RCTs Meta-analysis confirmed that both OS and PFS in non-squamous NSCLC patients are significantly improved by bevacizumab OS PFS Forest plots of hazard ratios (HRs) for (A) overall survival (OS) and (B) progression-free survival (PFS) from four randomised trials of bevacizumab (7.5 mg/kg or 15 mg/kg) added to standard chemotherapy, compared with chemotherapy alone, as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC; ECOG 4599, AVAiL, AVF-0757g and JO19907). Pooled HRs were computed using fixed-effect models. The bars indicate 95% confidence intervals (CI). The chi-squared test showed no significant heterogeneity between the trials. (OE, observed-expected). Soria, et al. Annals of Oncology 24: 20 30, 2013
29 Real-world effectiveness of treatment options in NSCLC: SEER analysis Owonikoko, et al. Oncologist :
30 ¼ Sheng J, Medicine 2015
31 SAiL: trial design (Phase IV study) First-line, advanced non-squamous NSCLC (n=2,212) Bevacizumab (7.5mg/kg or 15mg/kg) q3w + standard of care chemotherapy (up to 6 cycles) Bevacizumab to progression PD Graphical elaboration from text data Primary endpoint safety profile 86% of the population had adenocarcinoma histology Secondary endpoints time to disease progression (TTP) overall survival (OS) safety in CNS metastases Crinò L et al; Lancet Oncol. 2010;11:733-40
32 SAiL: confirmed efficacy of bevacizumab OS and TTP: secondary endpoints Months n=2,212 n=2,211* Median OS 1 Median TTP 1 *One patient was reported to have had disease progression before first treatment and was therefore not included in the TTP analysis Graphical elaboration from text data Crinò L et al; Lancet Oncol. 2010;11:733-40
33 SAiL: high disease control rate (DCR) with first-line bevacizumab-based therapy in clinical practice % CR/PR/SD/DCR* (%) 50 48% 37% 0 3% CR PR *Percentage is based on the number of patients with tumour assessment (n=2,036 [92.0%]) CR = complete response; PR = partial response; SD = stable disease Crinò L et al; Lancet Oncol. 2010;11: SD DCR Graphical elaboration from text data
34 TABLE 2. ARIES NSCLC (n = 1967) SAiL 7 (n = 2212) E (n = 434 ITT) AVAiL 4,5 7.5 mg/kg (n = 345 ITT) (n = 307 PP) AVAiL 4,5 15 mg/kg (n = 351 ITT) (n = 285 PP) Chemotherapy Regimen Investigator s choice Investigator s choice Paclitaxel + carboplatin Gemcitabine + cisplatin Gemcitabine + cisplatin Median follow-up, months (range) Median PFS, months (95% CI) 12.5 ( ) 12.5 (SD, ) 19 (for n = 851) 7 for PFS 12.5 for OS 7 for PFS 12.5 for OS 6.6 ( ) 7.8 ( ) a 6.2 (range N/A) 6.7 (range N/A) 6.5 (range N/A) Median OS, 13.0 ( ) 14.6 ( ) 12.3 ( ) 13.6 ( ) 13.4 ( ) months (95% CI) ORR b (%) a The SAiL study reported time to progression (TTP) outcomes instead of PFS. b Patients experiencing a complete response or a partial response; responses were assessed by investigators in ARIES. ARIES, Avastin Regimens: Investigation of Effectiveness and Safety; AVAiL, Avastin in Lung; CI, confidence interval; E4599, Eastern Cooperative Oncology Group 4599; ITT, intent-to-treat; N/A, not available; NSCLC, non small-cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PP, per protocol. Lynch TJ, JTO 2014
35 AVAPERL: trial design and patients disposition CR/PR/SD by RECIST Arm A: bevacizumab (n=125) Patients screened (n=414) First-line induction with Bev-cis-pem* (n=376) Patients randomised to maintenance* (n=253) 5 patients not treated PD Not eligible for randomisation (n=123) 123. patients not randomised 50 discontinued due to AEs 49 discontinued due to PD 9 patients died 7 withdrew consent 5 discontinued for other reasons 3 did not start treatment Arm B: bevacizumab + pemetrexed (n=128) 3 patients not treated Graphical elaboration from text data Barlesi, et al. J Clin Oncol. 2013;31:
36 AVAPERL: PFS from randomization Barlesi F et al. Annals Oncol May;25(5):
37 AVAPERL: OS from induction Barlesi F et al. Annals Oncol May;25(5):
38 POINTBREAK: phase III trial of bevacizumab with pemetrexed 4 cycles Previously untreated, stage IIIB or IV, non-squamous NSCLC, treated CNS mets, PS 0 1 (n=939) R 1:1 Pemetrexed + carboplatin + bevacizumab 15 mg/kg q3w Paclitaxel + carboplatin + bevacizumab 15 mg/kg q3w Pemetrexed + bevacizumab 15 mg/kg q3w Bevacizumab 15 mg/kg q3w Treat to PD Treat to PD Graphical elaboration from text data Primary endpoint OS Secondary endpoints ORR and DCR PFS and TTP safety and QoL Patel, et al. Clin Lung Cancer. 2009;10:252-6
39 POINTBREAK: OS (ITT population) Patel, et al. Clinical Lung Cancer, 2009; 4:
40 PRONOUNCE: Study Design Induction Phase q21d, 4 cycles Maintenance Phase q21d until PD Inclusion: Chemo-naïve patients PS 0/1 Stage IV, nonsquam Stable treated CNS mets R 1:1 Pemetrexed (folic acid & vitamin B 12 ) + Carboplatin Paclitaxel + Carboplatin + Bevacizumab Pemetrexed (folic acid & vitamin B 12 ) Bevacizumab Primary objective: Progression free survival without Grade 4 AE (G4PFS) Zinner et al, J Clin Oncol 31, 2013 (suppl; abstr LBA8003) ASCO Identifier: NCT Graphical elaboration from text data Secondary objectives Progression free survival (PFS) Overall survival (OS) Response rates (RR) and disease control rates (DCR) Safety and tolerability
41 PRONOUNCE: Primary endpoint: G4PFS (ITT) Proportion Pem+Cb: median G4PFS = 3.9 months Pac+Cb+Bev: median G4PFS = 2.9 months Log-rank p-value = HR (90% CI) = 0.85 ( ) Zinner et al, J Clin Oncol 31, 2013 (suppl; abstr LBA8003); ASCO 2013 Months Patients at risk Pem+Cb Pac+Cb+Bev
42 AvaALL: phase IIIb study of bevacizumab continued beyond progression in NSCLC Primary endpoint: OS Stage IIIB/IV non-squamous NSCLC treated with platinumdoublet (4 6 cycles) + bevacizumab PLUS > 2 cycles of bevacizumab maintenance PD 1 Randomise 1:1 SOC2* + bevacizumab PD 2 SOC3 + bevacizumab PD 3 SOC4 ± bevacizumab SOC2* SOC3 SOC4 n=600 Enroll Primary endpoint: OS Graphical elaboration from text data Secondary endpoints include PFS, safety, QoL and biomarker analysis *SOC2: labelled agents for second-line treatment of NSCLC SOC3 and beyond: choice of labelled agents is the investigator s choice Gridelli C, et al. Clin Lung Cancer. 2011;12:407-11
43 Beva troubles (the story of its short use) Is it a matter of toxicity? Is it a matter of costs? Is it a matter of patient selection?
44 Incidence of grade 3/4 AEs across trials Bevacizumab has a safe and tolerable profile 1 Planchard D., Expert Rev. Anticancer Ther. 11(8), (2011)
45 No increased bleeding risk in bevacizumabtreated patients with centrally located tumours Baseline risk factor for PH Central tumour location Yes No Total pts Pts who developed PH (n=13) 9 4 Matched control pts (n=42) Odds ratio (95% CI) 2.1 ( ) PH = pulmonary haemorrhage Graphical elaboration from text data While central tumor location was common, there was no correlation between this and the risk of pulmonary hemorrhage Sandler et al, J Clin Oncol 2009, 27:
46 Hypertension is manageable in bevacizumab-treated patients In SAiL, 85% of HTN events resolved or improved 85% and bevacizumab therapy was continued after 89% of HTN events 89% Resolved or improved Persisted Bevacizumab therapy continued Bevacizumab therapy interrupted or discontinued Crinò L et al; Lancet Oncol. 2010;11: Graphical elaboration from text data
47 SAiL: No increased bleeding risk with concomitant bevacizumab and anticoagulation The incidence of bleeding events, including grade 3 PH, was similar in patients receiving anticoagulants versus those not receiving anticoagulation therapy Dansin et al, Lung Cancer 2012; 76: Reck et al, Annals of Oncology 23: , 2012 CNS, central nervous system. a Pulmonary hemorrhage/hemoptysis. b Cerebral hemorrhage/hematoma. c Percentages are based on number of patients in each subgroup
48 Patients with CNS metastases can receive bevacizumab-based therapy Low risk of CNS bleeding across tumour types (>13,000 patients) Dataset 1 No. of enrolled patients No. of patients with CNS metastases A: 13 phase II/III trials 8,443 Bevacizumab: n=91 Non-bevacizumab: n=96 B: 2 open-label trials (ATHENA and SAiL) C: 2 prospective studies (ATLAS & PASSPORT) Rate of CNS bleeding (%) Bevacizumab arm Non-bevacizumab arm ,382 Bevacizumab: n= Bevacizumab: n= Graphical elaboration from text data 25 March 2009: EMA removed label restriction to allow patients with untreated CNS metastases to receive bevacizumab 2 1. Besse, et al. Clin Cancer Res ;16:
49 Global TL Consensus on bevacizumab safety Exclusion factors for bevacizumab Squamous histology Haemoptysis grade 2 Invalid exclusion factors Central tumour location Cavitation Full-dose anticoagulation Elderly Major vessel invasion = individual assessment No clinical or radiological features (including cavitation and central tumour location) have been shown to be reliable predictive factors for severe PH in bevacizumab-treated patients. Major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting, may predict PH. However, standardized radiological criteria for defining infiltration have not been established. Hypothetically, dilation of the bronchial artery could be a risk factor for PH, but no data exist to support this. Reck et al, Annals of Oncology 23: , 2012
50 No molecular selection (no party) Clinical selection FIT for CTX & BEVA FIT for CISPLATIN FIT for CBDCA UNFIT for a Doublet Courtesy - F De Marinis
51 Conclusions (pills of) Neoangiogenesis is a leading driver in NSCLC Reloaded interest with newer drugs Bevacizumab in a real first-line option with sound data No reliable predictive factors Need for careful clinical selection
Angiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationAntiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño
Antiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño Formigal, 24 de junio de 2016 Antiangiogénesis Sigue siendo una alternativa? Angiogenesis: A hallmark of cancer leading to malignant
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationTreatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives
Treatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives Prof. Christian Manegold Medical Faculty Mannheim University of Heidelberg Disclosures Consultancy: Hoffmann-La Roche, Pfizer,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationLung cancer is the leading cause of cancer-related death in the
ORIGINAL ARTICLE Bevacizumab Maintenance in Patients with Advanced Non Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory
More informationAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Richard D. Hall 1, Tri
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationPF , HKI 272 XL647, BIBW
Targeted Therapy for Lung Cancer? Emerging Novel targets for NSCLC 11 th UCSF/UCD Thoracic Oncology Conference 11/21/29 Sarita Dubey, M.D., Medical Oncology University of California, San Francisco Cytotoxic
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationBevacizumab treatment for advanced non small cell lung cancer: A case report
ONCOLOGY LETTERS 6: 1779-1783, 2013 Bevacizumab treatment for advanced non small cell lung cancer: A case report YUN FAN *, ZHIYU HUANG and WEIMIN MAO * Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationTargeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC)
46 The Open Lung Cancer Journal, 2010, 3, 46-56 Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC) Athanasios Kotsakis 1 and Taofeek K. Owonikoko *,2 Open Access 1 Division of Hematology-Oncology,
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationTargeting Angiogenesis in Advanced Non Small Cell Lung Cancer
Original Article CE 1235 Targeting Angiogenesis in Advanced Non Small Cell Lung Cancer Philip E. Lammers, MD, MSCI, and Leora Horn, MD, MSc Abstract Lung cancer is the leading cause of cancer-related mortality
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More information